Scarica l'app Stockscreener
73.56
1.29%
-0.96
Dopo l'orario di chiusura:
72.87
-0.69
-0.94%
Precedente Chiudi:
$74.52
Aprire:
$74.01
Volume 24 ore:
1.49M
Relative Volume:
0.94
Capitalizzazione di mercato:
$9.88B
Reddito:
$3.10B
Utile/perdita netta:
$586.71M
Rapporto P/E:
17.13
EPS:
4.2937
Flusso di cassa netto:
$605.57M
1 W Prestazione:
-5.84%
1M Prestazione:
-14.61%
6M Prestazione:
-15.11%
1 anno Prestazione:
+25.87%
Intervallo 1D:
$72.84
$74.49
Intervallo di 1 settimana:
$72.84
$78.69
Portata 52W:
$54.15
$101.40
Globus Medical Inc Stock (GMED) Company Profile
Nome
Globus Medical Inc
Settore
Industria
Telefono
610-930-1800
Indirizzo
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA
Compare GMED vs ABT, MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GMED
Globus Medical Inc
|
73.56 | 10.01B | 3.10B | 586.71M | 605.57M | 4.2937 |
ABT
Abbott Laboratories
|
103.36 | 182.09B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.62 | 117.54B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
270.01 | 105.63B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.10 | 65.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.77 | 49.67B | 6.30B | 1.07B | 1.09B | 1.8406 |
Globus Medical Inc Stock (GMED) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Aggiornamento | Needham | Hold → Buy |
| 2026-01-27 | Iniziato | TD Cowen | Buy |
| 2025-11-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-11-07 | Aggiornamento | Truist | Hold → Buy |
| 2025-10-28 | Ripresa | Stifel | Hold |
| 2025-05-27 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-01-10 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-08-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-05-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-03-18 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2023-10-20 | Iniziato | ROTH MKM | Buy |
| 2023-09-19 | Aggiornamento | Stifel | Hold → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-02-13 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-02-10 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-02-10 | Downgrade | Loop Capital | Buy → Hold |
| 2023-02-10 | Downgrade | Needham | Buy → Hold |
| 2023-02-10 | Downgrade | Truist | Buy → Hold |
| 2023-02-10 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-04-13 | Ripresa | Truist | Buy |
| 2022-03-28 | Iniziato | Wells Fargo | Overweight |
| 2022-01-04 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-12-13 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-29 | Iniziato | Loop Capital | Buy |
| 2021-02-18 | Ripresa | Needham | Buy |
| 2020-12-08 | Iniziato | Citigroup | Buy |
| 2020-10-20 | Iniziato | Stifel | Hold |
| 2020-08-06 | Reiterato | Needham | Buy |
| 2020-08-06 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2020-07-21 | Iniziato | Northland Capital | Market Perform |
| 2020-07-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-05-08 | Reiterato | Needham | Buy |
| 2020-03-18 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-01-08 | Iniziato | SunTrust | Buy |
| 2019-12-12 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2019-08-02 | Reiterato | Needham | Buy |
| 2019-05-24 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2019-05-03 | Reiterato | Needham | Buy |
| 2019-02-28 | Aggiornamento | UBS | Neutral → Buy |
| 2019-01-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-08-02 | Reiterato | Needham | Buy |
| 2018-06-27 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2018-06-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-05-03 | Reiterato | Needham | Buy |
| 2018-04-04 | Aggiornamento | Needham | Hold → Buy |
Mostra tutto
Globus Medical Inc Borsa (GMED) Ultime notizie
COO Q3 Earnings Top Estimates, Revenues Miss on Destocking, Stock Down - Zacks Investment Research
Audubon’s Globus Medical Brings Its 3-in-1 Surgical Imaging System to European Union - biobuzz.io
Zacks Industry Outlook Highlights Veracyte, Globus Medical and UFP Technologies - TradingView
Zacks.com featured highlights include Globus Medical, NetApp and Assurant - Yahoo Finance
3 Medical Instruments Stocks Banking on GenAI to Tackle Industry Woes - TradingView
Globus Medical Inc (GMED) Shares Fall 4.2% -- What GF Score of 9 - GuruFocus
Globus Medical Clears Excelsius3D for European Sales - MyChesCo
Globus Medical, Inc. (GMED) Stock Analysis: Healthcare Innovator with a 31.86% Upside Potential - DirectorsTalk Interviews
Globus Medical (GMED) Received CE Mark For Its Excelsius3D Imaging System - Yahoo Finance
Globus Medical Announces CE Mark for Excelsius3D™ Imaging System Excelsius3D™ – Intelligent 3-in-1 Imaging System Expands Excelsius™ Ecosystem in the European Union - Orthopedics This Week
Globus Medical Announces CE Mark for Excelsius3D™ Imaging System - Ortho Spine News
Globus Medical’s Excelsius3D imaging system receives CE mark - Yahoo Finance
Globus Medical receives CE mark for Excelsius3D imaging system By Investing.com - Investing.com South Africa
Globus Medical Inc (GMED) Stock Down 3.1% -- Now Undervalued? GF Score: 94/100 - GuruFocus
Globus Medical’s $840.5 Million War Chest — Robotics, Innovation & Expansion Converge! - Smartkarma
Globus Medical stock rises on EU approval for imaging system By Investing.com - Investing.com South Africa
Globus Medical Announces CE Mark for Excelsius3D Imaging System - Investing News Network
Globus Medical stock rises on EU approval for imaging system - Investing.com
Globus Medical Slides 3.1% Despite New Product Milestone as Investors Weigh Recent Growth Questions - Quiver Quantitative
Globus Medical Wins EU, UK Approval to Market Excelsius3D Imaging Platform - marketscreener.com
Globus Medical receives CE mark for Excelsius3D imaging system - Investing.com
One mobile system combines 3 types of medical imaging. Globus Medical can now sell it in the EU and UK. - Stock Titan
Audubon’s Globus Medical Acquires Duke Spinout Higgs Boson Health - biobuzz.io
3 Reasons Growth Investors Will Love Globus Medical (GMED) - Eastern Progress
Globus Medical Buys Higgs Boson to Expand Digital Care - MyChesCo
Globus Medical, Inc. (GMED) Investor Outlook: Analyzing a 24% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
M&A: Globus Medical Acquires Duke Incubator Higgs Boson Health to Expand Surgical Intelligence - HIT Consultant
BMO Capital Maintains Globus Medical(GMED.US) With Buy Rating, Maintains Target Price $94 - Moomoo
Wall Street Analysts Believe Globus Medical (GMED) Could Rally 25.03%: Here's is How to Trade - Yahoo Finance
Is Globus Medical (GMED) A Bargain On Its Robotics And Margin Growth Story? - Yahoo Finance
Globus Medical acquires digital health firm Higgs Boson By Investing.com - Investing.com Nigeria
Globus Medical Acquires Higgs Boson Health to Expand Digital Healthcare and Surgical Intelligence Ecosystem - Quiver Quantitative
Globus Medical announces AI acquisition with a 95% good-outcomes goal at 10 years - Stock Titan
Globus Medical acquires digital health firm Higgs Boson - Investing.com
Globus Medical, Inc. agreed to acquire Higgs Boson, Inc. - marketscreener.com
Globus Medical Inc (GMED) Stock Down 3.3% -- Now Undervalued? GF Score: 95/100 - GuruFocus
Globus Medical (GMED) Could Be 17% Undervalued On Its Robotics Growth Narrative - Sahm
Globus Medical (NYSE:GMED): A Decent Value Stock With Solid Fundamentals - ChartMill
Globus Medical (GMED) Stock Could Be Undervalued Following Margin Gains Update - Yahoo Finance
Globus Medical Inc (GMED) Stock Down 3.0% -- Now Undervalued? GF Score: 95/100 - GuruFocus
Globus Medical Director Stephen T. Zarrilli Executes Stock Options and Sells Shares on August 18, 2026 - Kalkine Media
Globus Medical Director Sold Shares Worth Over $2.1M - TradingView
Globus Medical (NYSE: GMED) director exercises options, sells 25,000 shares - Stock Titan
Globus Medical: The Dip Makes It Cheaper, Not Different (NYSE:GMED) - Seeking Alpha
Globus Medical: 7 Quarters Of Margin Expansion, Priced For None (NYSE:GMED) - Seeking Alpha
Globus Medical (NYSE: GMED) insider plans $2.2M sale - Stock Titan
Looking for a Growth Stock? 3 Reasons Why Globus Medical (GMED) is a Solid Choice - qz.com
Here is Why Growth Investors Should Buy Globus Medical (GMED) Now - Yahoo Finance
Is Revenue Growth Amid Margin Pressure Altering The Investment Case For Globus Medical (GMED)? - Sahm
Globus Medical (GMED) Stock Analysis: Navigating a 20% Potential Upside with Healthcare Innovation - DirectorsTalk Interviews
Assenagon Asset Management S.A. Sells 127,216 Shares of Globus Medical, Inc. $GMED - MarketBeat
Globus Medical Inc Azioni (GMED) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.29%
0.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):